Emyria Ltd · ASX:EMD
Emyria — Investor Presentation (October 2020)
32 slides from Emyria's investor presentation, Oct 14, 2020
Slide 1: Investor presentation October 2020
For personal use only Investor presentation October 2020 Michael Winlo - MD & CEO ASX:EMD DRAFT
Slide 2: Disclaimer and notices
Disclaimer and notices This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any ju
Slide 3: Funding history & milestones in first 6 months
Funding Funding history history & milestones & milestones in6first in first 6 months months For personal use only History Milestones • Listed on the ASX, 12 February 2020 (ticker: EMD) • $1m+ total contract value of data deals • Last reported cash position (Q2, 2020): $3.7m • 2,500 patients referred
Slide 4: Experienced board with medical focus
Experienced board with medical focus For personal use only Key Person Role Previous Experience Non-Executive 30 years of CEO and Board experience in medical and agrifood biotech companies. Chairman of Orthocell Ltd Dr Stewart Washer (ASX:OCC), regenera- tive medicine company, Founding Chairman and c
Slide 5: Deliver great care and insights
Deliver great care and insights For personal use only
Slide 6: Drivers of change in health care
Drivers of change in health care What’s needed? Typical model today Emyria today Potential future model For personal use only How Emyria is investing Doctor sees patient in “Doctor-in-your-pocket” - Care Building remote clinical “brick & mortar” clinics or smartphones facilitate self-care access mon
Slide 7: Emyria creates data products and technologies that accelerate novel drug development
Emyria creates data products and technologies that accelerate novel drug development and elevate care For personal use only for patients with unmet medical needs Emyria’s data products Novel treatments Emyria product registration Emyria Care Emyria Data Emyria Patients pharmacovigilance with unmet m
Slide 8: Emyria's leading products
Emyria’s leading products For personal use only Emyria Care Emyria Tech Emyria Data Emyria product registration Emyria pharmacovigilance * Australia-wide, * Cutting-edge remote * Unique clinical data independent clinical monitoring technology of value to drug service developers
Slide 9: Emyria accelerates novel drug development
For personal use only Emyria accelerates novel drug development
Slide 10: Novel treatments
Novel treatments We partner with research-focused Sponsors to safely administer novel and For personal use only unregistered treatments where evidence is lacking but the clinical need is great Revenue generation Emyria Clinical treatment Product QA service Patient Data pipeline selection checks desi
Slide 11: Emyria elevates care for patients with unmet medical needs
For personal use only Emyria elevates care for patients with unmet medical needs DRAFT
Slide 12: Emyria Care trains and develops our own clinical experts
Emyria Care Emyria trains and develops our own clinical experts For personal use only Dr Jennifer Dr Alistair Dr Phil Finch Morgan Vickery Dr Nelson Lau Dr Jennifer Tai Dr David Gunn Dr Ben Addison Pictured: Some of Emyria’s clinical team. For more details on our care team, please visit www.Emyria.c
Slide 13: Emyria Care creates Emyria Data
For personal use only Creates creates Emyria Care Emyria Data Emyria care Emyria data informs Informs
Slide 14: Emyria Care and Emyria Data
For personal use only creates Emyria Care Emyria Data We evaluate and provide We collect robust and ethically- individualised care for patients sourced clinical evidence with each who have failed “standard of care” consenting patient • 4 clinicsEmyria across Australia care • Emyria data Regulator-gr
Slide 15: Emyria generates revenues from care and insights
Emyria generates revenues from care and insights Data insights For personal use only Emyria Data revenue Unmet medical needs Collect data Insights Clinical trials Registration Monitoring Insomnia Chronic non-cancer pain Chemotherapy symptoms Autism Irritable Bowel Syndrome Cancer Pain Emyria Care Ep
Slide 16: Case Study - Bob
Case Study - Bob For personal use only • Vietnam Veteran | injured by fall in 1969 | multiple fractures • Chronic back pain | peripheral neuropathy from Agent Orange | PTSD • At initial visit: oxycontin | buprenorphine | pregabalin | gabapentin | PEA duloxetine – with little relief and side effects.
Slide 17: Emyria creates data products
For personal use only Emyria creates data products
Slide 18: Traditional drug development process
Traditional drug development process For personal use only Product registration Pharmacovigilance Initial market Potential authorisation indication expansion Preclinical Preclinical Studies studies Phase 1, 2, 3 clinical trials Post authorisation monitoring what is the drug? is it safe? is it still
Slide 19: Emyria product registration
For personal use only Emyria product registration Data insights + services to help drug developers obtain market authorisation (i.e. a “label claim”)
Slide 20: Emyria product registration
For personal use only Emyria product registration indication-specific dose response insights Global product registration strategic trial design support using anonymised real-world evidence clinical trial execution registration and repurposing submission support
Slide 21: Case Study - Zelira Therapeutics
Emyria product registration For personal use only Case Study - Zelira Therapeutics Emyria was approached in 2019 and provided insomnia-related outcome insights from Emyria’s real-world data. These insights supported a Phase 2 trial. In parallel, Emyria conducted a home-based Phase 1 clinical trial v
Slide 22: Global regulatory environment for cannabinoids
Global regulatory environment for cannabinoids For personal use only TGA (Australia) (USA) MHRA (UK) [09-Sep-20] TGA releases proposal to [05-Mar-20] FDA releases statement: [13-Oct-16] “We have come to the down schedule “low dose” CBD “To address the questions and opinion that products containing (
Slide 23: Emyria pharmacovigilance
For personal use only Emyria pharmacovigilance Data insights to monitor how a drug performs in the real-world
Slide 24: Emyria pharmacovigilance
For personal use only Emyria pharmacovigilance additional clinical indications Near real-time safety / adverse events pharmacovigilance for novel products providing real-world product use patterns evidence cost effectiveness
Slide 25: Case Study - Spectrum Therapeutics
Emyria pharmacovigilance For personal use only Case Study - Spectrum Therapeutics Emyria approached in 2019 to develop a pharmacovigilance product registry to include safety data for Australian patients taking Spectrum products seen through Emerald Clinics. After just 6 months, Emyria’s PV services
Slide 26: Emyria creates technologies
For personal use only Emyria creates technologies
Slide 27: Emyria technology
For personal use only Emyria technology patient-centric care in the home improve clinical efficiency and evidence capture Emyria is investing in the future of care helps clinical team stay connected to patients supports delivery of data- driven care plans
Slide 28: Emyria technology
For personal use only Emyria technology Health screening, powered by your smartphone and backed by a clinical team Emyria has a strategic Emyria’s Openly App partnership with Mt is registered with Sinai’s Precision the TGA as a Class 1 Recovery Team to Medical Device develop Openly please see ASX an
Slide 29: Openly workflow
Openly workflow Simple, Scalable Screening in Seconds Actionable Insights Deployed to a person’s mobile Openly is easy to use, enabling Openly aggregates population device, Openly is quickly frequent screenings and health data to manage risk and deployed to large populations objective clinical measu
Slide 30: Future development of Emyria's lead products
Future development of Emyria’s lead products For personal use only Emyria Care Emyria Tech Emyria Data Emyria product registration Emyria pharmacovigilance * Clinical service in new * Develop health * More data deals geography (UK) screening service * Emyria insights that * Increase diversity of * T
Slide 31: Upcoming speaking engagements
Upcoming speaking engagements For personal use only “Real World Evidence & its impact 15 ARCS Conference Thursday 15 October on clinical, regulatory and market OCT 09.00 - 10.30am, AEDT access” 29 AusBiotech 2020 Thursday 29 October “Evidence based medicine and OCT precision dosing” 11.45am - 12.30p
Slide 32: Contact Information
For personal use only Contact Information Michael Winlo: mwinlo@emyria.com Investors: investors@emyria.com Media: media@emyria.com General: info@emyria.com ASX:EMD DRAFT